Shares of Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.02 and traded as high as $2.00. Cortexyme shares last traded at $1.85, with a volume of 168,423 shares traded.
Cortexyme Stock Performance
The stock has a market cap of $53.07 million, a P/E ratio of -0.59 and a beta of 1.40. The firm has a 50-day moving average price of $1.61 and a 200-day moving average price of $1.03.
About Cortexyme
(
Get Free Report)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
Before you consider Cortexyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cortexyme wasn't on the list.
While Cortexyme currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
